Transcription of Public Assessment Report Mutual Recognition Procedure
{{id}} {{{paragraph}}}
Example: biology
Public Assessment Report Mutual Recognition Procedure
Public Assessment Report Mutual Recognition Procedure SAYANA PRESS 104 ml suspension for injection PL 00057/1093; UK/H/0960/002/DC medroxyprogesterone acetate Pfizer LimitedPAR SAYANA PRESS 104 ml suspension for injection UK/H/0960/002/DC 2 LAY SUMMARY This is a summary of the Public Assessment Report (PAR) for SAYANA PRESS 104 suspension for injection (PL 00057/1093; UK/H/0960/002/DC). It explains how SAYANA PRESS 104 suspension for injection was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product. For ease of reading, throughout this PAR, the product SAYANA PRESS 104 suspension for injection will be called SAYANA PRESS. For practical information about using SAYANA PRESS, patients should read the Package Leaflet or contact their doctor or pharmacist.
Public Assessment Report Mutual Recognition Procedure SAYANA PRESS 104 mg/0.65 ml suspension for injection PL 00057/1093; UK/H/0960/002/DC Medroxyprogesterone acetate
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Package leaflet: Information for the patient Provera, Medroxyprogesterone acetate, PROVERA Medroxyprogesterone acetate, PROVERA ® Medroxyprogesterone acetate, PROVERA, Consumer Medicine Information Template, Approved Prescription Products for Menopausal, NDC Billing Reference, Nevada, Contraceptive Services Only, NeedyMeds